This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bull of the Day: Jazz Pharmaceuticals (JAZZ)
by Kevin Cook
Trading at just 11X next year's $13 EPS, this innovator is just getting started fighting cancer with new FDA approvals and partnerships
Zacks.com featured highlights include Lantheus Holdings, Jazz Pharmaceuticals, Gray Television, Aetna and Uniti Group
by Zacks Equity Research
Zacks.com featured highlights include Lantheus Holdings, Jazz Pharmaceuticals, Gray Television, Aetna and Uniti Group
Immunogen Inks Deal With Jazz Pharma to Develop ADC Molecule
by Zacks Equity Research
ImmunoGen (IMGN) and Jazz Pharma announced a strategic collaboration to develop and commercialize antibody-drug conjugate products.
ImmunoGen (IMGN) in Focus: Stock Moves 17.3% Higher
by Zacks Equity Research
ImmunoGen (IMGN) was a big mover last session, as the company saw its shares rise over 17% on the day amid huge volumes.
5 Excellent Value Stocks Based on Low PEG Ratio
by Zacks Equity Research
While P/E alone fails to identify a true value stock, PEG helps find the intrinsic value of a stock.
Enanta Pharmaceuticals (ENTA) Looks Good: Stock Adds 9.6% in Session
by Zacks Equity Research
Enanta Pharmaceuticals, Inc. (ENTA) was a big mover last session, as the company saw its shares rise over 9% on the day.
Ironwood Pharma's Combination Gout Drug Gets FDA Approval
by Zacks Equity Research
Ironwood Pharmaceuticals, Inc. (IRWD) announced that the FDA has approved Duzallo for the treatment of hyperuricemia in patients with uncontrolled gout.
Rally Set to Resume: Buy These 5 Value Picks on the Dip
by Swarup Gupta
Morgan Stanley believes that conditions for a Bull Run remain in place.
Jazz Pharmaceuticals Arm Announces $500M Senior Notes Offer
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) announces private offering of exchangeable senior notes to qualified institutional buyers to raise proceeds and repay debt.
Endo International (ENDP) Jumps: Stock Rises 6.9%
by Zacks Equity Research
Endo International (ENDP) was a big mover last session, as the company saw its shares rise almost 7% on the day amid huge volumes.
Jounce Therapeutics (JNCE) Jumps: Stock Moves 7.4% Higher
by Zacks Equity Research
Jounce Therapeutics, Inc. (JNCE) moved big last session, as its shares jumped over 7% on the day.
Jazz Pharma (JAZZ) Q2 Earnings & Revenues Miss, View Intact
by Zacks Equity Research
Jazz Pharma's (JAZZ) earnings and revenues miss estimates. However, the top line rises year over year owing to higher sales of the company's marketed drug, Xyrem.
Can Jazz Pharma (JAZZ) Spring a Surprise in Q2 Earnings?
by Zacks Equity Research
Jazz Pharma's (JAZZ) lead drug, Xyrem, is likely to deliver a strong performance in Q2, thanks to label expansion efforts.
AVEO's Kidney Cancer Candidate Gets CHMP Recommendation
by Zacks Equity Research
AVEO Pharmaceuticals, Inc. (AVEO) announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its lead candidate, Fotivda (tivozanib), for the treatment of advanced renal cell carcinoma (RCC).
Why Is Jazz Pharmaceuticals (JAZZ) Down 3.3% Since the Last Earnings Report?
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jazz Pharma Sleep Disorder Candidate Positive in Phase III
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) announced positive efficacy results from studies evaluating its lead pipeline candidate, JZP-110, in adult patients with excessive sleepiness (ES) associated with narcolepsy and obstructive sleep apnea (OSA).
Jazz Pharmaceuticals' Vyxeos NDA Granted Priority Review
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) announced that the New Drug Application (NDA) for its experimental leukemia candidate Vyxeos has been accepted for priority review by the FDA.
BioLineRx Makes Regulatory Submission for Trial of BL-8040
by Zacks Equity Research
BioLineRx Ltd. (BLRX) announced that it has submitted a regulatory filing required to start a phase Ib study for BL-8040 in combination with Roche Group's (RHHBY) Tecentriq (atezolizumab).
Jazz Pharmaceuticals (JAZZ) Misses Q1 Earnings & Sales
by Zacks Equity Research
Jazz Pharmaceuticals Public Limited Company (JAZZ) reported first-quarter 2017 earnings of $1.41 per share, which narrowly missed the Zacks Consensus Estimate of $1.42.
Jazz Pharma (JAZZ) Q1 Earnings: Stock Likely to Disappoint?
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) is scheduled to report first-quarter 2017 results on May 9, after the market closes.
Jazz Pharma Completes NDA Filing for Leukemia Drug to FDA
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) recently announced that it has completed the rolling submission of a new drug application (NDA) to the FDA, seeking approval for its leukemia candidate, Vyxeos.
Jazz Pharma (JAZZ) Up 7.6% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Jazz Pharma (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jazz Sleep Disorder Drug Positive in Phase III Studies
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) recently announced positive efficacy results from two phase III studies evaluating the safety and efficacy of its lead pipeline candidate JZP-110 for the treatment of excessive sleepiness.
Jazz Initiates Phase III Study for Narcolepsy Candidate
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) recently announced the initiation of patient enrollment in a phase III study evaluating the efficacy and safety of its pipeline candidate, JZP-258, for the potential treatment of adult narcolepsy patients.
Jazz Pharma (JAZZ) Q4 Earnings Beat, Sales Miss Estimates
by Zacks Equity Research
Jazz Pharmaceuticals Public Limited Company (JAZZ) reported fourth-quarter 2016 earnings of $1.91 per share which beat the Zacks Consensus Estimate of $1.65.